ENSC NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Ensysce Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.25 USD
-3.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -43.6% below the Trend Line and sits at 0.9% of its 52-week range. The latest completed week returned -3.2%, after a -10.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 18 out of 100
Latest Close 0.25 USD 31 Jul 2026
1W Return -3.2% latest completed week
4W Return -10.9% short-term follow-through
12W Return -27.8% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 37.68% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.2% Latest completed week; four-week move -10.9%. Indicator stack 0/89 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 37.68% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 50 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -43.6% below the Trend Line and sits at 0.9% of its 52-week range. The latest completed week returned -3.2%, after a -10.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.09

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.9% over four weeks, -27.8% over 12 weeks, and -87.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-3.2%
4W-10.9%
12W-27.8%
26W-65.2%
52W-87.7%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.35Latest activity-pressure read.
Pressure change184.8%Four-week change in activity pressure.
Leadership-79.23Latest relative-leadership reading.
RS change1.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength62/100Blend of value, momentum, and quality. Underlying universe rank 39; rank 1 is best.
Value55/100Relative valuation strength. Underlying universe rank 46; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum56/100Medium-term price momentum. Underlying universe rank 45; rank 1 is best.
Growth56/100Revenue and earnings growth. Underlying universe rank 45; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-243.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-112.8%
Gross profit retained from each unit of revenue.
Operating margin
-287.6%
Operating profit retained from revenue.
Free-cash-flow margin
-198.7%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-24.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-99.0%
Net share repurchases relative to market value.
Shareholder yield
-99.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 50 relevant articles.

10 positive · 34 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-90.8%Distance below the 52-week high.
13-week volatility9.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher8 of 2618 weeks finished lower.
Best week+56.8%Week of 27 Feb.
Worst week-36.5%Week of 6 Feb.
Latest week-3.2%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains0
Flat weeks0
Modest losses2
Sharp losses16
Recent vol9.4%13-week weekly-return volatility.
Base vol15.2%52-week weekly-return volatility.
Up/down split18/32Count of positive and negative weeks in the 52-week window.
Average skew12.1% / -11.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape22/100

Trend, activity pressure, participation, and risk combine to a 22/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 37.68%

Next-week expectancy is negative with a 37.68% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 100 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 50 relevant articles.

ENSC|Ensysce Biosciences Inc|Price:0.253|Chg%:+0.002 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.25 USD-3.2%0.45 USD6.89 USD1.35-79.231.1MOff
24 Jul 20260.26 USD-7.6%0.47 USD7.07 USD1.27-79.181.3MOff
17 Jul 20260.28 USD4.8%0.50 USD7.26 USD1.07-78.6421.1MOff
10 Jul 20260.27 USD-5.0%0.53 USD7.46 USD0.75-81.112.1MOff
3 Jul 20260.28 USD-5.6%0.57 USD7.65 USD0.47-80.441.7MOff
26 Jun 20260.30 USD10.9%0.61 USD7.84 USD0.17-79.815.9MOff
19 Jun 20260.27 USD8.0%0.66 USD8.01 USD0.11-83.185.3MOff
12 Jun 20260.25 USD-1.1%0.71 USD8.20 USD0.13-84.495.5MOff
5 Jun 20260.25 USD-9.6%0.77 USD8.43 USD0.29-84.438.1MOff
29 May 20260.28 USD-11.8%0.83 USD8.65 USD0.40-84.102.4MOff
22 May 20260.32 USD13.7%0.89 USD8.87 USD0.42-82.025.4MOff
15 May 20260.28 USD-20.0%0.95 USD9.10 USD0.41-84.4797.6MOff
8 May 20260.35 USD-10.0%1.02 USD9.36 USD0.34-81.231.0MOff
1 May 20260.39 USD-6.1%1.09 USD9.66 USD0.34-78.621.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.